The utility of CAMid℠ is that it helps to identify a potential target for therapy. Sometimes, there are FDA-approved options for a given mutation, such as mutations in BRAF which are present in 40-50% of patients and may be treated with one of three combinations (vemurafenib plus cobimetinib, dabrafenib and trametinib, encorafenib and binimetinib). Other times there are clinical trials of agents predicted to have some benefit in patients whose tumor has a mutation in a certain gene. In either case, testing is very useful in understanding which types of treatments may be an option for a patient, even if the first choice in therapy is going to be an immune therapy and not a mutation-targeted therapy.
Detection of mutations in cancer patients are usually done with cancer tissues and increasingly using circulating tumor DNA (ctDNA). However, mutation detection using tumor tissue is often hampered by insufficient numbers of quality tumor content. In fact, 40% of tumor samples from patients have insufficient DNA - leading to unreliable test results.
CAMid℠ solves this problem using DNA and RNA from amplified tumor cells. These are pure, quality, living tumor cells created from a patient's own tumor sample. Using amplified tumor cells ensures we always have enough quality samples and is why our test is more sensitive than other genomic tests.
Our lab is CLIA Registered. We are preparing to go commercial with CAMid℠ as soon as we obtain our CLIA Certification this summer. In the meantime, CAMid℠ is for research use only. If you would like more information or are interested in ordering, please fill out the contact form and we will reach out to you.
Rapidly produces a perpetual supply primary cancer cells from a variety of patient tumor specimens.
Store your original tumor or amplified tumor cells in an account that never runs out of living tumor cells.